
MicroRNAs (miRNAs) are short non-coding RNAs (ncRNAs) that regulate gene expression post-transcriptionally, guiding Argonaute-containing RNA-Induced Silencing Complexes (RISC) to complementary messenger RNA (mRNA) sequences to repress translation and promote degradation. Because a single miRNA can influence hundreds of transcripts, these molecules offer access to regulatory nodes, including transcription factors and protein-protein interaction interfaces, that conventional antibodies and small-molecule inhibitors cannot reach, constrained as these are by target “druggability”. This has driven sustained interest in miRNA-driven therapeutics—mimics, antagomiRs, and antisense oligonucleotides—as a route to modulating disease networks directly at the RNA level. This narrative review synthesizes current understanding of miRNA biogenesis, delivery platforms such as lipid nanoparticle (LNP) encapsulation and chemically modified oligonucleotides, as well as miRNA dysregulation across oncological, cardiovascular, and renal pathologies. We also examine the clinical trajectory of representative candidates (Cobomarsen, Remlarsen, Miravirsen) and the roadblocks—off-target effects, delivery inefficiency, and immunogenicity—that have limited their translation. Finally, we review emerging machine learning (ML) and deep learning (DL) applications to miRNA target prediction and biomarker discovery, including tools that outperform established prediction algorithms, considering whether these computational approaches address, rather than merely reframe, the field’s translational bottlenecks. We conclude that miRNA therapeutics remain constrained by delivery and safety challenges, while artificial intelligence (AI)-assisted discovery represents a plausible, yet clinically unproven, avenue of progress.
miRNA; non-coding RNA therapeutics; lipid nanoparticles; gene silencing; oligonucleotide delivery; miRNA biomarkers; post-transcriptional regulation